Integrin-mediated drug targeting
    2.
    发明授权
    Integrin-mediated drug targeting 有权
    整合素介导的药物靶向

    公开(公告)号:US07220824B1

    公开(公告)日:2007-05-22

    申请号:US10070208

    申请日:2000-08-28

    IPC分类号: A61K38/14

    CPC分类号: C07D491/22

    摘要: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units. The preferred linking units guarantee serum stability of the conjugate of cytostatic and αvβ3 integrin antagonist and at the same time the desired intracellular action in tumour cells as a result of their enzymatic or hydrolytic cleavability with release of the cytostatic.

    摘要翻译: 本发明涉及通过优选连接单元与α-β3整联蛋白拮抗剂连接而具有肿瘤特异性作用的细胞抑制剂。 优选的连接单元保证细胞生长抑制和α3β3整联蛋白拮抗剂的缀合物的血清稳定性,同时由于它们的结合,肿瘤细胞中期望的细胞内作用 酶促或水解裂解性,释放细胞抑制作用。